Tag:

Sanofi

Latest Headlines

Latest Headlines

Sanofi and MannKind launch Afrezza DTC ad campaign in stealth mode

Surprise! It's a DTC campaign for Sanofi and Mannkind's Afrezza. The low-key ad launch of "Surprise, It's Insulin" came with little fanfare, unlike the media and industry scuttlebutt surrounding the drug itself, which has been closely watched and analyzed for more than a year.

China's ZAI Lab in-licenses global rights on Sanofi NSCLC candidate

China's ZAI Lab has in-licensed a novel multi-kinase inhibitor aimed at a non-small cell lung cancer candidate from Sanofi as the firm led by well-known biotech executive Samantha Du builds its on deep Greater China trial and regulatory experience.

With solid Q2, Sanofi CEO says M&A could be part of growth strategy

Sanofi's new CEO, Olivier Brandicourt, has a new company structure he is trotting out, a new potentially hot cholesterol-lowering drug to launch and now is able to take credit for a full quarter's worth of financial results that outperformed the street's best guesses. He even said today that Sanofi may be ready to do some wheeling and dealing, having so far stayed out of the M&A melee that has been going on all year.

Express Scripts: Pricey PCSK9 drugs poised to 'wreak havoc'

Last week, Sanofi revealed a $14,600 sticker for new PCSK9 med Praluent that far exceeded the price tag analysts expected. And unsurprisingly, leading PBM and vocal price critic Express Scripts is none too thrilled about it. 

Sanofi's dengue vax protects two-thirds of people aged 9 and up: NEJM

As it works to introduce its dengue vaccine in endemic countries around the world, Sanofi Pasteur this week touted efficacy results from two Phase III studies in a move to help build the case for wide uptake.

Sanofi looks to go to FDA in Q4 as diabetes combo LixiLan hits goal in trial

Sanofi has gotten a bit of positive reinforcement in its efforts to revive its diabetes business in the U.S. Experimental combo med LixiLan has thrown off some promising results, hitting its primary goal in a late-stage trial.

Sanofi's LixiLan hits PhIII goal, moving one step closer to a Novo showdown

Sanofi's diabetes business--long the company's growth driver--is in for a slowdown over the next few years, and any sales expansion the French drugmaker sees will depend, in part, on new U.S. launches. Now, experimental combo med LixiLan is one step closer to joining that launch group after nailing its main goal in a late-stage trial.

Sanofi's diabetes combo clears a clinical hurdle in a race with Novo Nordisk

Sanofi's combination of a Type 2 diabetes treatment and a long-acting insulin met its main goal in a Phase III trial, the company said, setting up an FDA application later this year.

To hardest-to-treat patients, Sanofi's Praluent looks cheap

Payers may already be cooking up ways to reduce the $14,600 yearly price of Sanofi and Regeneron's new PCSK9 drug, Praluent. But to some patients, the drug is a bargain. 

Sanofi hands Regeneron $1.8B for new immuno-oncology pact

After winning approval for their PCSK9 drug Praluent last week, longtime partners Sanofi and Regeneron are back at it with a new collaboration. The French pharma giant will pay at least $1.8 billion in a new immuno-oncology deal that includes an early-stage checkpoint inhibitor.